Differences in clinical characteristics and cardiovascular disease risk prediction among Chinese women with polycystic ovary syndrome phenotypes: a cross-sectional study - Top-Institutions - MDSpire

Differences in clinical characteristics and cardiovascular disease risk prediction among Chinese women with polycystic ovary syndrome phenotypes: a cross-sectional study

  • By

  • Ziye Gong

  • Danyang Li

  • Xuan Li

  • Jinjin Tian

  • Jing Guo

  • Yuying Zhao

  • Yin Lu

  • Shan Gao

  • Ming Li

  • April 10, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Cardiology
    • Reproductive Medicine

  • #2

    Harvard Medical School / Massachusetts General Hospital
    Harvard Medical School / Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Cardiology
    • Epidemiology

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Endocrinology
    • Cardiology
    • Obstetrics and Gynecology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Endocrinology
    • Cardiology
    • Women's Health

  • #5

    Peking University Health Science Center
    Peking University Health Science Center

    Beijing, Beijing

    Key Differentiators

    • Endocrinology
    • Cardiology
    • Epidemiology

Original Source(s)

Differences in clinical characteristics and cardiovascular disease risk prediction among Chinese women with polycystic ovary syndrome phenotypes: a cross-sectional study

  • by Ziye Gong, Danyang Li, Xuan Li, Jinjin Tian, Jing Guo, Yuying Zhao, Yin Lu, Shan Gao, Ming Li

  • April 10, 2026

Related Content

Uterine morphology in normogonadotropic anovulation: a comparative study of polycystic ovary syndrome and hypothalamic-pituitary-ovarian dysfunction

Retraction: Integrated multi-omics analysis reveals complement component 3 as a central driver of immune dysregulation in polycystic ovary syndrome

  • June 5, 2026

Thyroid autoimmunity does not delineate a cardiometabolic or androgenic phenotype in women with polycystic ovary syndrome: a pre-specified cross-sectional analysis